Eli Lilly and Company Partners with Ginkgo Bioworks for AI Drug Discovery
What happened
Eli Lilly and Company reached a deal with Ginkgo Bioworks to utilize the biotechnology company's billions of data points to accelerate drug discovery using artificial intelligence. Eli Lilly and Company has launched Lilly TuneLab, which uses AI and machine learning to potentially speed up drug discovery efforts.
From fool.com
Why it matters
The partnership allows Eli Lilly and Company to leverage Ginkgo Bioworks' data points through AI to potentially speed up drug discovery. Ginkgo Bioworks reported that its revenue totaled $20.2 million in the quarter ending June 30, a decline from $39.1 million in the same period last year, as the company undergoes restructuring.
From fool.com
Who's involved
- Eli Lilly and CompanyAmerican pharmaceutical company utilizing AI and data points for drug discovery
- Ginkgo BioworksAmerican biotechnology company providing billions of data points and cellular programming services
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Ginkgo BioworksSpeculative
Ginkgo Bioworks could see increased demand for its data points and AI services, potentially boosting revenue
- Eli Lilly and CompanySpeculative
Eli Lilly and Company may reduce the time and cost associated with drug discovery efforts
- TD CowenSpeculative
TD Cowen might face pressure on its prior negative investment thesis regarding Ginkgo Bioworks
Keep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Ginkgo Bioworks
American biotechnology company
Nothing else this week.